ANA Pollution (2.06.2026)
Dr. Jack Cush reviews the news, journal articles and regulatory news from this past week on RheumNow.com
Read Article
NEW FROM ACR: See data for patients with RA who achieved remission at 6 months with a JAKi and maintained response at 2 years in a real-world study. Click to learn more about long-term outcomes.
Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/GVfoF2LJez https://t.co/segRc0jrof
Dr. John Cush @RheumNow( View Tweet )
DERM on RheumNow PODCAST (January 2026)
The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and https://t.co/nX0iWp2J0I
Dr. John Cush @RheumNow( View Tweet )
Giant Cell Arteritis Outcomes in Canada
A retrospective cohort study of patients with giant cell arteritis (GCA) demonstrates relapses are common and seen in nearly half of patients, were common after treatment is stopped and is not effectively averted by methotrexate (MTX).
Read Article
Potential New Rheumatology Drugs for 2026. These have had successful phase III RCTs and will need to be reviewed by regulators:
** deucravacitinib (Sotyktu) Tyk2 inhib for PsA
** Icotrokinra (Icotyde) oral IL-23i for psoriasis
** brepocitinib TYK2/JAK1 inhibitor for https://t.co/CQmfjIDMp3
Dr. John Cush @RheumNow( View Tweet )
Are JAK Inhibitors Better at Pain Relief in RA?
Among rheumatoid arthritis (RA) patients who responded to upadacitinib (Rinvoq) or adalimumab, those receiving upadacitinib had significantly less residual pain with treatment, according to a post hoc analysis of phase III trial https://t.co/QrbwlxIm3d
Dr. John Cush @RheumNow( View Tweet )
Emergencies, Independence & Hemorrhage (1.23.2026)
Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com
Read Article
Are JAK Inhibitors Better at Pain Relief in RA?
MedPage Today
Among rheumatoid arthritis (RA) patients responding to upadacitinib (Rinvoq) or adalimumab, those receiving the former had significantly less residual pain with treatment, according to a post-hoc analysis of phase III trial data.
Read Article
Retrospective study of recombinant zoster vaccine Rheumatic (RMD) pts on DMARDs (32% JAKi) (114) vs 65 normals. HZoster reactivation: no controls vs 1in RMD. 1 Dz flare requiried steroids. Minor AE (ISR, HA, myalgia) seen in 17.5% & 21.5% w/ 1st & 2nd dose. RZV is safe in RMD https://t.co/Mu3OyA4EOD
Dr. John Cush @RheumNow( View Tweet )
The 2025 Rheumatology Year in Review
The year 2025 presented numerous advances in rheumatology and related inflammatory and autoimmune disorders ranging from several new groundbreaking FDA approvals/indications, drug developments, game-changing guidelines and practices that will impact patient care for rheumatic diseases.
Read Article
Advanced Practitioner Biologic Prescriptions for Psoriasis
Advanced practice clinicians (APCs; nurse practitioners and physician assistants) deliver a large share of US dermatologic care, accounting for 37% of clinicians and 27% of dermatology visits by 2020. A current JAMA Dermatology reports APC drug spending trends in dermatology, with a focus on
Read Article
2026 Resolutions (1.9.2026)
Dr. Jack Cush reviews the news, announcements and journal articles from this past week on RheumNow.com. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!
Read Article
Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis
Editor's note: This article was originally published April 22, 2025, and is being shared again as part of RheumNow's 'Best of 2025' series as we close out the year. Enjoy!
Read Article
Best of 2025: Variability of Guidelines on the Perioperative Use of DMARDs in Rheumatic Diseases Patients
More effective treatments in patients with rheumatic diseases have resulted in less need for major surgery, yet a substantial number of RMD patients will undergo surgery often in the setting of DMARDs use. A scoping review looked at numerous clinical practice guidelines/recommendations for the
Read Article
GC dose and tapering may influence serious infection risk in patients with GCA. Discover the key safety outcomes observed during a year of JAKi therapy in a Phase 3 trial. Sponsored by AbbVie Medical Affairs +Health Impact. https://t.co/xIC7Vqx659 https://t.co/6n3XfXeeg2
Dr. John Cush @RheumNow( View Tweet )
NEW ONLINE ACR POSTER: 2-year efficacy and safety outcomes with a JAKi in patients with GCA. Click to see the latest results from a Phase 3 trial presented at ACR 2025, sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/Tm8m43ZXBM https://t.co/GWLPR5y3d2
Dr. John Cush @RheumNow( View Tweet )
Best of 2025: Dermatomyositis Reviewed
Researchers from the University of Pennsylvania have published an open-access review of dermatomyositis (DM) - its manifestations, hallmark cutaneous features, etiopathogenesis and treatment options.
Read Article
Telling You Where to Go (12.19.2025)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow. Who would've thunk - a PsA FMF connection? Labs to diagnose SSc-ILD? IgA-RF may be important or RZV may not work in JAK inhibitor treated patients? https://t.co/bwF89L9Z7R
Dr. John Cush @RheumNow( View Tweet )
Best of 2025: Overview of the VEXAS Syndrome
A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome.
Read Article
Japanese retrospective study-194 #RA pts Rx w/ JAK inhib (74 vaccinated w/ recombinant zoster (RZV) & 120 Not-Vax). H.zoster lower w/ RZV (4.8/100PY) vs UnVax (7.8/100PY) w/ overall efficacy of 59.1%. RSV Vax pts who got HZ had signif lower lymphocyte #s, higher SDAI & CDAI. https://t.co/vJJRflJ23x
Dr. John Cush @RheumNow( View Tweet )
Japanese retrospective study-194 #RA pts Rx w/ JAK inhib (74 vaccinated w/ recombinant zoster (RZV) & 120 Not-Vax). H.zoster lower w/ RZV (4.8/100PY) vs UnVax (7.8/100PY) w/ overall efficacy of 59.1%. RSV Vax pts who got HZ had signif lower lymphocyte #s, higher SDAI & CDAI. https://t.co/4VMWPhzXeL
Dr. John Cush @RheumNow( View Tweet )
British Society of Rheumatology Guideline for Monitoring DMARDs
The British Society of Rheumatology has published an update to their previous 2017 BSR/BHPR guideline regarding the use and monitoring of DMARDs (disease-modifying anti-rheumatic drugs) used to treat systemic autoimmune rheumatic diseases (SARDs).
Read Article
DMARD Treatment Lags for Minority Groups with Rheumatoid Arthritis
MedPage Today
Use of disease-modifying anti-rheumatic drugs (DMARDs) for rheumatoid arthritis (RA) was markedly lower among all major racial-ethnic minority groups in the U.S. compared with white patients, analysis of federal survey data indicated, even after adjusting for income, education, and other factors
Read Article
DERM on RheumNow (November 2025)
The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side https://t.co/mX0Hv1RRF9
Dr. John Cush @RheumNow( View Tweet )
Retrospective study of 39 pts w/ MDA5 + DM-ILD Rx w baricitinib. 31 (79.5%) had improvement in Gottron’s, heliotrope, dyspnea, HRCT score, ferritin, LDH, steroid dose & 6 mo survival (87% vs. 70%, p = 0.047). https://t.co/RCTbBsCkeV https://t.co/dF8I0gF4Dy
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
Daily Download
Topic Videos
Rx Updates (filtered for Topic)
Therapeutic Updates
The Impact of Obesity on Psoriatic Arthritis
Sponsored by Lilly Medical Affairs
Obesity is common in PsA and may worsen disease activity and reduce treatment effectiveness through shared inflammatory pathways. Weight intervention may improve outcomes and support achievement of targets of disease control.
Read Post